<DOC>
	<DOC>NCT00537056</DOC>
	<brief_summary>To learn whether FDG PET/CT and DCE MRI are better predictors of response to therapy than the current standard of care (CT or MRI).</brief_summary>
	<brief_title>Evaluating Sunitinib Therapy in Renal Cell Carcinoma Using F-18 FDG PET/CT and DCE MRI</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma, Renal Cell</mesh_term>
	<mesh_term>Kidney Neoplasms</mesh_term>
	<mesh_term>Fluorodeoxyglucose F18</mesh_term>
	<mesh_term>Sunitinib</mesh_term>
	<criteria>Measurable disease by RECIST criteria Pathologic diagnosis of renal cell cancer Advanced (stage IV) renal cell cancer Karnofsky performance status of (KPS&gt;70) Consent to participate in the clinical trial Patients who cannot complete a PET/CT scan. Pregnant women. Healthy volunteers. Patients participating in other research protocols will be excluded from this study. Metallic implants (prosthesis, ICD, pacemakers), since these are contraindications for MRI.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2013</verification_date>
</DOC>